Category
The TSLP-blocking antibody met its goals in a Phase 3 eosinophilic esophagitis trial, setting up a potential third indication and a challenge to Sanofi’s Dupixent.
The Tokyo AI firm and Julien Orts’s NMR lab will combine machine learning with atomic-resolution spectroscopy to target intrinsically disordered proteins in cancer.
Definium’s dissolving LSD tablet beat placebo in a large trial for generalized anxiety disorder, with effects seen within days — sending its shares up.
In the 106-patient HOPE-3 trial, boys and young men on deramiocel lost arm and elbow function markedly slower than those on placebo, ahead of an August FDA decision.
The partnership pairs miRecule’s RNA-design platform with peptide-based delivery to reach tissues current RNA therapies struggle to treat, starting with neuromuscular disease.
From a whole-genome map built on over a trillion lab-grown neurons, the partners pinpointed a novel neuro target in 15 months — the first payoff from a collaboration worth up to $12 billion.
The Series B will fund Phase 2 and Phase 3 studies of dotinurad, a uric-acid-lowering therapy already approved in several Asian markets.
The company said its next-generation pyruvate kinase activator failed to show enough differentiation, ceding ground to a rival Novo Nordisk therapy.
A UConn project won a $500,000 grant to make low-cost DHA powder from microalgae grown on brewery waste, targeting a key nutrient gap for pregnant women.
The antibody drug improved muscle strength and function in adults with inflammatory muscle disease, setting up a potential label expansion for a therapy already generating billions.
LTG-001, an oral Nav1.8 blocker, eased post-surgical pain and cut opioid rescue use in a 343-patient trial published in the New England Journal of Medicine.
Despite Phase 3 efficacy, Sanofi says its OX40 drug wouldn't meaningfully beat standard care — the latest setback for a once-promising class of immune drugs.
Combining an antibody-drug conjugate with the PARP inhibitor olaparib overwhelmed non-small cell lung cancer’s DNA-repair defenses — and roused the immune system — in preclinical models.
The new nonprescription tablet pairs acetaminophen and naproxen sodium for 12-hour pain relief — the first fixed-dose combo of the two sold over the counter.
The CRISPR biotech, which silences genes without cutting DNA, priced a modest offering in a cautious market — a notable reopening for gene-editing listings.
A large proteomics analysis of a landmark Parkinson’s study is now public, aiming to sort patients into subtypes and speed more targeted, biology-driven therapies.
The partnership will use quantum algorithms to design better photosensitizers — molecules that kill tumor cells when hit with light — a task classical computers struggle with.
In three women with stubborn, antibiotic-resistant infections, pairing viruses that kill bacteria with a microbiome transplant reduced recurrences and antibiotic use — but the study is tiny.
Zipalertinib plus chemo so clearly slowed a hard-to-treat form of lung cancer that the trial was stopped early — setting up a fight with drugs from J&J and AstraZeneca.
Vertex pays $28 million upfront and will fund all R&D for multispecific antibodies AbCellera discovers, pushing T-cell engagers beyond cancer into autoimmunity.
A new screening platform systematically finds drugs that tag disease proteins for disposal — including targets that conventional inhibitors can’t touch.
The Korean biotech will tap Eli Lilly’s labs, scientists and infrastructure to speed its RNA-based gene therapies — an incubator arrangement, not an acquisition.
The manufacturer will produce an AAV9 gene therapy for GM2 gangliosidosis — a group of fatal inherited disorders — developed with Queen’s University ahead of planned clinical trials.
Ultragenyx’s Genglycos delivers a working gene to the liver in glycogen storage disease type Ia, aiming to free patients from the relentless routine of round-the-clock cornstarch dosing.
In the Phase 3 SAFFRON trial, adding Hutchmed’s Orpathys to Tagrisso delayed progression and extended overall survival in EGFR-mutated lung cancer that had developed a MET-driven resistance.
While the industry chases GLP-1 agonists for weight loss, Amylyx went the other way — and its GLP-1 antagonist cut severe hypoglycemic events by 55% in a late-stage trial.
Hibsago (bepirovirsen) becomes the first therapy cleared anywhere aimed at functionally curing chronic hepatitis B — a milestone in a disease that infects hundreds of millions worldwide.